AG
Artal Group Portfolio holdings
AUM
$930M
1-Year Return
3.57%
This Quarter Return
+22.25%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$4.52B
AUM Growth
+$640M
(+17%)
Cap. Flow
-$931K
Cap. Flow
% of AUM
-0.02%
Top 10 Holdings %
Top 10 Hldgs %
91.49%
Holding
100
New
10
Increased
15
Reduced
23
Closed
3
Top Buys
| 1 |
Goldman Sachs
GS
|
$22.2M |
| 2 |
Neurocrine Biosciences
NBIX
|
$10.4M |
| 3 |
MDCO
Medicines Co
MDCO
|
$9.5M |
| 4 |
Incyte
INCY
|
$9.44M |
| 5 |
Nektar Therapeutics
NKTR
|
$7.82M |
Top Sells
| 1 |
Alibaba
BABA
|
$27M |
| 2 |
ATH
Athene Holding Ltd. Class A Common Shares
ATH
|
$12.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$6.81M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$6.77M |
| 5 |
ZTO Express
ZTO
|
$6.28M |
Sector Composition
| 1 | Consumer Staples | 44.29% |
| 2 | Healthcare | 31.71% |
| 3 | Consumer Discretionary | 21.77% |
| 4 | Financials | 0.83% |
| 5 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Atara Biotherapeutics
ATRA
$89.9M
| $7M | 0.12% |
20,000
| – | – |
|
|
TSRO
27
DELISTED
TESARO, Inc.
TSRO
| $6.99M | 0.12% |
50,000
| – | – |
|
|
28
ZTO Express
ZTO
$14.5B
| $6.98M | 0.12% |
500,000
-450,000
| -47% | -$6.28M |
|
29
Ionis Pharmaceuticals
IONS
$9.46B
| $6.87M | 0.12% |
135,000
-115,000
| -46% | -$5.85M |
|
30
e.l.f. Beauty
ELF
$7.59B
| $6.8M | 0.12% |
250,000
| – | – |
|
|
RDUS
31
DELISTED
Radius Health, Inc.
RDUS
| $6.79M | 0.12% |
150,000
-100,000
| -40% | -$4.52M |
|
32
Seres Therapeutics
MCRB
$165M
| $6.78M | 0.12% |
30,000
| – | – |
|
|
ARAV
33
DELISTED
Aravive, Inc. Common Stock
ARAV
| $6.11M | 0.11% |
58,333
+8,333
| +17% | +$873K |
|
34
AnaptysBio
ANAB
$590M
| $5.98M | 0.1% |
250,000
+205,310
| +459% | +$4.91M |
|
|
JUNO
35
DELISTED
Juno Therapeutics, Inc.
JUNO
| $5.98M | 0.1% |
200,000
| – | – |
|
36
MetLife
MET
$54.4B
| $5.49M | 0.1% |
112,200
-112,200
| -50% | -$5.49M |
|
|
AXDX
37
DELISTED
Accelerate Diagnostics
AXDX
| $5.47M | 0.1% |
+20,000
| New | +$5.47M |
|
38
MacroGenics
MGNX
$123M
| $5.25M | 0.09% |
300,000
| – | – |
|
39
Sarepta Therapeutics
SRPT
$1.93B
| $5.06M | 0.09% |
150,000
-50,000
| -25% | -$1.69M |
|
40
TG Therapeutics
TGTX
$5.06B
| $5.03M | 0.09% |
+500,000
| New | +$5.03M |
|
41
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.73M | 0.08% |
850,000
+350,000
| +70% | +$1.95M |
|
|
CCXI
42
DELISTED
ChemoCentryx, Inc.
CCXI
| $4.68M | 0.08% |
500,000
-46,278
| -8% | -$433K |
|
|
FPRX
43
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $4.52M | 0.08% |
+150,000
| New | +$4.52M |
|
44
AC Immune
ACIU
$216M
| $4.4M | 0.08% |
500,000
| – | – |
|
|
AKAO
45
DELISTED
Achaogen, Inc.
AKAO
| $4.35M | 0.08% |
200,000
+140,000
| +233% | +$3.04M |
|
46
Syndax Pharmaceuticals
SNDX
$1.39B
| $4.19M | 0.07% |
300,000
+100,000
| +50% | +$1.4M |
|
|
SIOX
47
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $4.06M | 0.07% |
21,875
-9,375
| -30% | -$1.74M |
|
48
Lineage Cell Therapeutics
LCTX
$274M
| $4.04M | 0.07% |
1,465,383
| – | – |
|
49
Intellia Therapeutics
NTLA
$1.25B
| $4M | 0.07% |
250,000
| – | – |
|
|
SGEN
50
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.88M | 0.07% |
75,000
| – | – |
|